Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1158/1078-0432.CCR-14-1071

http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-14-1071
suck pdf from google scholar
C4252869!4252869 !25281695
unlimited free pdf from europmc25281695
    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25281695 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
pmid25281695
      Clin+Cancer+Res 2014 ; 20 (23 ): 5875-81
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Ramucirumab: successfully targeting angiogenesis in gastric cancer #MMPMID25281695
  • Javle M ; Smyth EC ; Chau I
  • Clin Cancer Res 2014[Dec]; 20 (23 ): 5875-81 PMID25281695 show ga
  • Gastric cancer is the fourth most common cancer globally and represents the second most common cause of cancer-related mortality. Early detection, aggressive surgical resection, and postoperative adjuvant therapy have led to survival improvement for early-stage gastric cancer, particularly in Asian countries. Unfortunately, advanced gastric cancer continues to pose a formidable challenge with few gains being reported recently. Trastuzumab was the first targeted agent to be approved for the treatment of advanced gastric cancer in 2010. The failure of the AVAGAST trial was a setback for antiangiogenic therapy for this disease. Ramucirumab is a monoclonal antibody that binds to VEGF-R2 and prevents its activation. The recent REGARD trial was a randomized phase III trial of ramucirumab vs. placebo for patients with advanced, pretreated gastric cancer that met its primary endpoint of increased overall survival. The toxicity of ramucirumab was modest in this setting, with an increased risk of grade 3 or higher hypertension (8% vs. 3%, with ramucirumab and placebo, respectively). The subsequent RAINBOW trial of paclitaxel plus ramucirumab vs. paclitaxel plus placebo for advanced pretreated gastric cancer confirmed the survival advantage of this antiangiogenic agent in gastric cancer. Ramucirumab is the first FDA-approved therapy for advanced gastric cancer after prior chemotherapy.
  • |Angiogenesis Inhibitors/pharmacology/*therapeutic use [MESH]
  • |Antibodies, Monoclonal, Humanized [MESH]
  • |Antibodies, Monoclonal/pharmacology/*therapeutic use [MESH]
  • |Antineoplastic Agents/pharmacology/*therapeutic use [MESH]
  • |Clinical Trials as Topic [MESH]
  • |Humans [MESH]
  • |Molecular Targeted Therapy [MESH]
  • |Neovascularization, Pathologic/*drug therapy [MESH]
  • |Ramucirumab [MESH]
  • |Stomach Neoplasms/*drug therapy/metabolism/*pathology [MESH]
  • |Treatment Outcome [MESH]
  • |Vascular Endothelial Growth Factor A/metabolism [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box